AI-Driven Prompt Engineering in Drug Discovery: The SwaLife AI Discovery Suite as an Intelligent Ideation Platform

Abstract

Drug discovery remains constrained by high costs, extended timelines, and inefficient ideation processes despite advances in computational biology. The early stages of drug discovery-hypothesis formulation and experimental design-remain largely manual, subjective, and time-consuming. The SwaLife AI Discovery Suite represents a paradigm shift by integrating artificial intelligence into the conceptual design phase of drug discovery through automated, structured prompt generation. Rather than performing simulations or analyses, this platform generates context-specific scientific prompts that guide researchers through target identification, lead discovery, optimization, and preclinical planning. By bridging the gap between computational insights and experimental execution, the suite enhances reproducibility, standardizes workflows, and accelerates scientific ideation across pharmaceutical and academic research environments. This review examines the architecture, applications, advantages, and future scope of AI-powered prompt engineering in drug discovery, positioning it as a transformative tool for the next generation of therapeutic development.